Alan talks of superiority, but I doubt we need to do that!
Non inferiority is normally good enough for this type of thing, but I get that superiority will have a massive impact on the field (and the ASX)!
The confidence is astounding.
"The primary objective of the study is to compare the detection rate of sites of prostate cancer recurrence, as determined by number of lesions per patient, between 64Cu-SAR-bisPSMA and 68Ga-PSMA-11 positron emission tomography (PET)/computed tomography (CT)."
CU6 Price at posting:
$6.67 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)